Synonyms: flavopiridol | HL 275 | HMR 1275 | L 86-8275 | L 868275 | MDL-107826A | NSC-649890
Compound class:
Synthetic organic
Comment: Alvocidib is a selective inhibitor of cyclin-dependent kinase (CDK) 2 and CDK4 [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Alvocidib has progressed to Phase 2 clinical evaluation for anti-cancer potential. Click here to link to ClinicalTrials.gov's full list of alvocidib trials. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Alvocidib is a CDK kinase inhibitor [1,7] which causes cell-cycle arrest and subsequent apoptosis of cancer cells [2,4]. |